FDA Hoping To Shift Some ‘Cures’ Initiatives Toward User Fee Negotiations
This article was originally published in The Tan Sheet
Executive Summary
As Rep. Upton signals an impending deal, FDA Acting Commissioner Stephen Ostroff strikes a more conciliatory tone than his predecessor, Margaret Hamburg.